The global herpes marker testing market is categorized based on various diagnostic tests and by vaccines and drugs used to treat oral herpes and genital herpes.
New York, NY -- (SBWIRE) -- 11/17/2016 -- Herpes is a type of infection caused by the herpes simplex virus (HSV). Herpes is mainly categorized into two forms: oral herpes and genital herpes. Oral herpes leads to the occurrence of cold sores around the face and mouth. Genital herpes is a sexually transmitted disease which affects the genital organs, buttocks, and anal area. Other herpes infections can affect the skin, eyes, and other parts of the body. HSV can be dangerous in newborn babies and people with weak immune systems. There are two types of HSV occurrences in the environment: HSV type 1 and HSV type 2. HSV type 1 primarily causes cold sores, and HSV type 2 leads to genital herpes. Most people get HSV type 1 in their childhood and adult stages. This virus can be spread by skin-to-skin contact with an adult who carries the virus. Most people get HSV type 2 through sexual contact. Some people do not report any symptoms of herpes. However, others get sores near the area where the virus has entered into the body. These sores turn into blisters and become itchy and painful.
The global herpes marker testing market is categorized based on various diagnostic tests and by vaccines and drugs used to treat oral herpes and genital herpes. Based on diagnostic technologies, the global herpes marker testing market covers molecular diagnostic technologies, monoclonal antibodies, immunoassays, differential light scattering, liposome, flow cytometry, chromatography, diagnostic imaging, and gel microdroplets.
View Sample Report @ http://www.persistencemarketresearch.com/samples/4185
In terms of geography, North America dominates the global herpes market testing market due to increased awareness about various forms of herpes in the region. The U.S. represents the largest market for herpes marker testing in North America, followed by Canada. In Europe, countries such as Germany, France, the U.K., Italy, and Spain account for a major share of the herpes marker testing market. This market is expected to expand at a significant rate in Asia over the next five years. This is due to the setting up of manufacturing facilities by various companies in the region. Moreover, factors such as increasing awareness about herpes and rise in population are also driving the market growth in the region. Countries such as India, China, and Japan are expected to be the fastest growing herpes marker testing markets in Asia.
In recent times, advancements in diagnostic technologies and increased demand of therapeutic products for the treatment of this medical condition are among the key drivers of the global herpes marker testing market. Factors such as increased investments in R&D in the pharmaceuticals sector, and the introduction of innovative drugs have also fueled the growth of this market. The ongoing development of drugs with properties such as improved safety and high patient compliance are also supporting the growth of the global herpes marker testing market.
However, stringent regulations by various governments hamper the growth of the global herpes marker testing market. Moreover, factors such as the risks of complications and side effects associated with vaccines have hindered the growth of the market. Increasing mergers and acquisitions of diagnostic technologies providers, and rapid product launches are some major trends in the global herpes marker testing market.
Request TOC (desk of content material), Figures and Tables of the report: http://www.persistencemarketresearch.com/toc/4185
The key companies operating in this market include Abbott Laboratories, Danaher Corporation, Becton, Dickinson and Company, bioMérieux, Bio-Rad Laboratories, Inc, Cepheid, Inc., Thermo Fisher Scientific, Inc., Siemens AG, DiaSorin, EIKEN CHEMICAL CO., LTD., Hologic, Life Technologies, and Novartis.